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PHYSIOLOGY OF BILE FORMATION
The liver is instrumental for maintaining enterohepatic circulation of bile salts. Bile salts are synthesized in a multistep cascade consisting of 16 enzymes catalyzing 17 reactions in hepatocytes 1 and secreted into the canaliculi, from were they enter the biliary tree [2] [3] [4] . In the biliary tree, the composition of bile with bile salts is modified and drained to the gall bladder, from where it enters the duodenum. In the duodenum, bile salts promote the digestion of fat and absorption of lipids and fat soluble vitamins 5, 6 . Bile salts are reclaimed to more than 90 % in the small intestine and transported back to the liver via the portal circulation. In the liver, bile salts are taken up again from the sinusoidal blood plasma and their journey to the intestine restarts 7 .
For efficient transport of bile salts from the sinusoids into the canaliculi as well as for controlling this process, hepatocytes are equipped with an elaborate array of transporters and regulatory mechanisms. Regulation of bile salt flow across hepatocytes is crucial, as bile salts are amphipathic molecules and display detergent properties. Hence, any surplus of bile salts within hepatocyte can become cytotoxic or even lethal to the cells.
In the basolateral plasma membrane, bile salts are taken up predominantly in a sodium dependent manner and to a minor portion via sodium independent processes. The sodium dependent uptake of bile salts is mediated by the sodium-taurocholate cotransporting polypeptide NTCP (SLC10A1) and shows a preference for conjugated bile salts 7, 8 . Sodium independent uptake of bile salts is fostered by organic anion transporting polypeptides or OATPs (SLCOs), namely OATP1B1 and OATP1B3 2, 9 . A third OATP, OATP2B1 is also expressed in hepatocytes but does not mediate transport of conjugated bile salts 2, 10 . OATPs are also mediators of hepatocellular drug and xenobiotic uptake whereby OATP1B1 and OATP1B3 exhibit considerable overlap in their substrate specificity. Both, NTCP and OATPs are subject to considerable interindividual differences in their hepatocellular expression levels. Knowledge on intracellular transport of bile 6 salts from the basolateral to the apical plasma membrane is still scarce, but it is assumed that binding proteins are involved. Canalicular export occurs against a steep concentration gradient and is mediated by a member of the ATP-binding cassette (ABC) transporter family: the bile salt export pump BSEP (ABCB11) 7, 11, 12 . The rate limiting step in the overall transport from the portal blood into bile is located to the canalicular membrane of hepatocytes 2, 13 . Hence, proper functioning of BSEP is essential for keeping the potentially cytotoxic bile salts at a low intracellular level in hepatocytes. Consequently, mutations leading to a non-functional BSEP protein were associated with familial cholestatic syndromes, the so called progressive familial intrahepatic cholestasis type 2 4 . Furthermore, as bile formation is an isoosmotic process, bile salts are a major driving force for the generation of canalicular bile flow. In addition to bile salts, canalicular bile contains lipids. Phosphatidylcholine is the major lipid constituent and its release from the extracellular leaflet of the canalicular membrane into bile is mediated by MDR3 or ABCB4. This ABC transporter acts as a phosphatidylcholine translocator supplying phosphatidylcholine to the outer hemileaflet of the canalicular membrane 14 . From there, phosphatidylcholine is released into bile by the detergent action of bile salts 15 . Mutations in the gene coding for MDR3 lead to progressive familial intrahepatic cholestasis type 3 16 . In primary bile, phosphatidylcholine and bile salts form mixed micelles, which act as acceptors for poorly water soluble substances, such as cholesterol 15 . The release of cholesterol from the canalicular membrane into bile is facilitated by the heterodimeric transporter ABCG5/ABCG8 17 .
A reduction of bile flow represents a pathophysiologic situation and is called cholestasis.
Metabolism of bile salts within hepatocytes leads to sulfated and glucuronidated bile salts, particularly in cholestatic conditions 18, 19 . Such bile salt derivatives are excreted into bile via the multidrug resistance protein MRP2 (ABCC2) 20 , or back into the sinusoids by MRP3 and MRP4 7 intracellular bile salts in hepatocytes. In addition, the heterodimeric organic solute transporter OSTα-OSTβ is also expressed in the basolateral membrane and might act as an additional salvage system 22 . The relative contribution of these three adaptive efflux systems is at the moment not fully understood and needs to be worked out in detail.
NTCP has a rather restricted substrate specificity and transports in addition to bile salts sulfated compounds such as bromosulfophthalein and sulfated steroid metabolites 7, 8, 23, 24 . Furthermore, in heterologoues expression systems NTCP transports bile salt-drug conjugates and sulfated thyroxin. Taken together, NTCP acts as the key hepatocellular bile salt uptake system, but may also contribute to hepatocellular handling of additional compounds and even drugs (see below).
NTCP transports one bile salt molecule together with two sodium ions and is therefore electrogenic 25 . Consequently, it can take up bile salts against a concentration gradient into hepatocytes.
OATPs transport a large variety of endogenous substrates, metabolic end products as well as xenobiotics, such as for example bile salts, estrogen metabolites, drugs and toxins 10, 26, 27 . In hepatocytes, OATP1B1 and OATP1B3 are the two key uptake transporters for unconjugated and conjugated bile salts and for hydrophobic, anionic xenobiotics, while OATP2B1 is so far considered to be mainly a transporter for bromosulfophthalein and steroid sulfates. OATP1B1
and OATP1B3 have a large overlap in their substrate specificity. It is therefore difficult to predict the individual contribution of either of the two transporters for the uptake of a given bile salt or a given drug. For example, in heterologous expression systems all hepatocytes OATPs mediate transport of rosuvastatin 28 . Most interestingly, in a recent genome wide SNP association study with patients on a high dose simvastatin treatment only OATP1B1 variants were identified as a risk factor for myopathy 29 . This can be taken as evidence that OATP1B1 is the functionally 8 relevant simvastatin (and most likely also other statin) uptake system in hepatocytes. The transport mechanism of OATPs is not known in detail, but they are believed to act as organic anion exchangers. Glutathione, glutathione-conjugates, oxidized glutathione as well as bicarbonate have been demonstrated to act as counteranions [30] [31] [32] [33] . In a recent study, evidence was presented that many OATPs indeed exchange bicarbonate for anions during the transport step and that most OATPs show higher transport rates at low extracellular pH 34 . Elucidation of the exact transport mechanism of the OATPs is however important as this will allow to predict, whether
OATPs have the potential to transport drugs against a concentration gradient into hepatocytes.
Such a mechanism would certainly contribute to drug toxicity in hepatocytes. In this context, coadministration of the OATP inhibitor rifampicin with glibenclamide in healthy volunteers leads to an increase of the AUC and of Cmax of glibenclamide 35 . In rat studies, glibenclamide was found to be 50 times higher concentrated in the liver as compared to the serum, suggesting a concentrative uptake mechanism into hepatocytes 36 .
BSEP has a narrow substrate specificity and transports mainly monanionic, conjugated bile salts 11, 12 . There is a variation in its substrate pattern between species, as for example human BSEP, but not rat Bsep transports the bile salt metabolite taurolithocholate-3-sulfate 37, 38 . Bsep transports barely any unconjugated bile acids 39 . This in vitro finding is supported in vivo by the observation that patients with a defect in bile acid conjugation have very little unconjugated bile acids in their bile 40 . BSEP is an electrogenic transporter and requires hydrolysis of ATP for transport activity 11, 41 . .
INCIDENCE AND DIAGNOSTIC CRITERIA OF CHOLESTASIS OF PREGNANCY
Intrahepatic cholestasis of pregnancy (ICP) is an acquired form of cholestasis, which is observed in otherwise healthy pregnant women with a normal medical history. It usually occurs in the second and third trimester of pregnancy, when serum concentrations of estrogens and progesterone reach their peak 50, 51 and is characterized by pruritus, elevated concentrations of bile salts, transaminases and rarely also of bilirubin in serum [52] [53] [54] [55] . The suggested pathogenic key role of female sex hormones is further supported by the rapid cessation of cholestatic symptoms after delivery 56 , the higher incidence of ICP in twin pregnancies 50 and the increased susceptibility of affected patients to develop intrahepatic cholestasis under oral contraception 57 .
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The incidence of ICP varies widely, originally ranging from 0.05 to >20% between different ethnic groups and geographical locations, with highest incidence rates reported for women with Araucanian Indian descent in Chile (for review see 54 ). In Caucasian populations of the United
States and Europe, incidence rates vary between 0.5 and 1.5%, with highest rates observed in Elevation of fasting serum total bile acid concentrations > 10mol/L may be the first and only laboratory abnormality in ICP 61, 62 . Specifically, serum cholic acid becomes the primary bile acid in ICP women in contrast to normal pregnant women and nonpregnant women, in whom its proportion is almost similar to chenodeoxycholic acid. This results in a marked elevation of the cholic/chenodeoxycholic acid ratio compared to pregnant women without ICP [63] [64] [65] . Other laboratory findings reflecting cholestasis include variable elevations in the serum concentrations of alkaline phosphatase, 5' nucleotidase, total and direct bilirubin and transaminases. Elevation of alkaline phosphatase levels is not specific of cholestasis during pregnancy due to the placenta isoenzyme, and the extent of transaminases elevation varies between 2-fold to 10-fold the upper limit of normal 58 .
Surprisingly, the serum concentrations of gamma glutamyl transpeptidase (GGT) are normal or only modestly elevated in most patients with ICP and might allow conclusions about the underlying defect in bile acid transport. Specifically, there is indication that elevated GGT levels indicate an impairment of MDR3 function, while GGT is normal in BSEP-related forms of estrogen-associated cholestasis 66 . Therefore, GGT might be useful to clinically distinguish between MDR3 and BSEP-related forms of estrogen-related cholestasis, as it is already done for progressive forms of inherited familial intrahepatic cholestasis 42, 67 .
PATHOPHYSIOLOGY OF STEROID INDUCED CHOLESTASIS
Clinical evidence based on serum levels of estrogens during pregnancy linked steroid hormones with intrahepatic cholestasis of pregnancy 68, 69 . Progesterone and its metabolites could in addition contribute to the pathogenesis of cholestasis of pregnancy 51, 64, 70 . Alternately, oral contraceptives can also lead to cholestasis 71 69 . In animal experiments, the steroid metabolites estradiol-17β-glucuronide and progesterone sulfate have been demonstrated to lead to acute cholestasis immediately after application 48, 72 .
From studies with rats treated for 5 days with high (usually 50 mg/kg body weight) ethinylestradiol, a model for estrogen-induced cholestasis, the following pathophysiologic picture emerged: Sodium-dependent uptake of taurocholate into basolateral liver plasma membrane vesicles is reduced by about 40 % and the v max of ATP-dependent bile salt transport into canalicular vesicles was reduced by 60 %. Also, the transport of dinitrophenylglutathione was markedly reduced. These functional data were paralleled by a 40 % decrease of bile flow 73 . 76, 78 . Also, the canalicular water channel aquaporin-8 is down-regulated in the canalicular membrane leading to a reduced water permeability of this membrane 79 . The basolateral salvage transporter Mrp3 is massively upregulated in ethinylestradiol treated rats at the mRNA and protein level 80, 81 . Therefore, high levels of estrogens clearly alter the expression pattern of key hepatocellular bile salt and drug transporters. Estradiol seems to act predominantly via estrogen receptor a, as in mice with a disrupted gene for this receptor neither the expression of the uptake transporters Ntcp, Oatp1a1
and Oatp1a4, nor the expression of the efflux transporter Bsep is affected 82 . In human females, the depot estrogen ethinylestradiol propanolsulphonate leads to a significant increase of total serum bile salts. Among the different bile salt species, the most pronounced effect was observed with taurine conjugates 83 . As this was paralleled with an increase in secondary bile salts, this study suggests a mild cholestatic phenotype due to the estrogen.
In a 5 day treatment regimen with ethinylestradiol of Wistar and TR -rats, which lack functional Mrp2, cholestasis was observed in both strains 84 . In contrast, the acute cholestatic action of estradiol-17β-glucuronide critically depends on expression of Mrp2, as this estrogen metabolite does not cause cholestasis in TR -rats 49 . In less than 30 minutes, treatment of rats with a bolus of estradiol-17β-glucuronide leads to a rapid internalization of a fraction of Mrp2 and Bsep into a 13 subapical, vesicular compartment [85] [86] [87] . This internalization is dependent on Ca 2+ -dependent protein kinase C 88 .
In summary, the molecular events in estrogen induced cholestasis affect many transport systems in the basolateral and canalicular membrane, whereby the uptake side seems to be mainly affected at the transcriptional level, while in the canalicular export site posttranscriptional processes predominate.
Steroid induced cholestasis is not exclusively associated with estrogens and/or progesterones.
The usage of androgenic or anabolic steroids, for example by competitive and noncompetitive athletes or body builders [89] [90] [91] can lead to liver injury including bland cholestasis 92 . Liver injury by this class of steroids is typically induced by compounds, which are alkylated at the 17α-position. Androgenic or anabolic steroid induced cholestasis can lead to severe jaundice 93, 94 , which may be prolonged 95 and accompanied with severe pruritus 96 . The literature on pathogenetic mechanisms of androgenic or anabolic steroid induced cholestasis is scarce.
Evidence from rat studies has been presented that the pericanalicular microfilaments are lost 97 .
Given the structural similarity of androgenic or anabolic steroids to estrogens, it is tempting to speculate that additionally similar mechanisms as with estrogens may apply to the pathogenesis of androgenic or anabolic steroid induced cholestasis.
GENETICS OF CHOLESTASIS OF PREGNANCY
Besides hormonal and most likely environmental factors, genetic susceptibility constitutes a risk factor to develop ICP. A genetic predisposition has been suspected based upon the strong regional clustering, the higher prevalence in female family members of patients with ICP and the susceptibility of ICP-patients to develop intrahepatic cholestasis under other hormonal challenges such as oral contraception 57 . In the last decade, mutations and polymorphisms in the canalicular 14 transporter proteins BSEP and MDR3 have both been associated with the development of ICP. A pathogenic role of genetically determined MDR3 dysfunction was first discussed upon the observation that female members of a large consanguineous family with one family member suffering from progressive intrahepatic cholestasis experienced typical recurrent episodes of ICP 98 . These observations were subsequently verified in pedigree and case-control studies, investigating the pathogenic role of heterozygous MDR3 mutations in different populations.
Strong evidence for a role of MDR3 genetic variation came from a Swiss cohort, were the extent of MDR3 genetic variation in 21 unrelated Caucasian women with ICP was compared to that observed in healthy pregnant control women 66 . In this collective, 47% of ICP patients had elevated GGT levels and 77% of these patients carried ICP-specific MDR3 mutations, including three splicing consensus mutation. These findings were later confirmed by a Swedish study, reporting the association of specific MDR3 haplotypes and severe cholestasis in 12% of 52 observed ICP cases compared to 0% in the control group 99 . Furthermore, a large Italian study in 80 women found heterozygous MDR3 mutations in 4% of cases 100 . A MDR3 splicing site mutation was detected as causative locus for the development of ICP in a large consanguineous family of Mennonite kinship 101 . Very interestingly, the same genetic locus was associated with the development of gallstone disease, which makes it very tempting to think that the higher prevalence of gallstone disease observed in ICP women could also be related to MDR3 dysfunction. In contrast, a study in Finland failed to demonstrate a pathogenic role of MDR3 mutations in ICP, pointing towards the heterogenous pathogenic nature of this disease 102 .
In contrast to MDR3, the pathogenic role of BSEP genetic variation in ICP has only recently emerged. Biochemical workup of ICP-patients subsequently allowed the differentiation between high and low GGT forms of ICP, suggesting the involvement of different transporter pathways.
While high GGT values were present in the majority of ICP-patients with an MDR3 mutation, genetic BSEP dysfunction was postulated in low GGT cases 98, 103 . Two Swiss studies conducted in independent ICP collectives first suggested the BSEP p.V444A polymorphism as ICP susceptibility factor, with the homozygous and heterozygous state for the alanine in position 444
being significantly more frequent in ICP women than in healthy pregnant controls 66, 104 . Very interestingly, the BSEP genotype in position 444 also correlated with serum bile acid levels, with carriers of the alanine showing higher serum bile acid levels than carriers of the valine allele.
These findings were recently confirmed in two independent ICP cohorts comprising a total of more than 400 patients, were alanine homo-and heterozygotes were significantly more frequent in the ICP collectives. In the same study, heterozygosity for the BSEP mutations p.E297G, p.D482G and p.N591S formerly associated with benign and progressive forms of familial intrahepatic cholestasis type 2 were found in four, one and two ICP patients, respectively, allowing the extrapolation that 1% of European ICP cases are caused by these mutations 105 .
While the molecular and mechanistic basis for p.V444A and p.N591S were not apparent, in-silico structural and functional analysis suggests that p.E297G and p.D482G destabilizes the protein fold of BSEP leading to decreased taurocholate transport in case of p.E297G 105, 106 . In addition, decreased hepatic BSEP expression 107, 108 , and very recently, significantly reduced hepatic mRNA levels 109 . Although the effect of this variant on MDR3 expression has not been studied, it is likely that activation of the MDR3 promoter is also reduced.
In line with this, a recent report of an ICP patient suffering from alterations in three genes:
p.S320F in MDR3 (previously described in a patient with ICP 113 ), p.A444V in BSEP and c.-
1G>T in FXR
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, again highlights the role of FXR as a factor associated with ICP.
These observations in intrahepatic cholestasis of pregnancy can be translated to other estrogenrelated forms of cholestasis, such as cholestasis seen with the use of oral contraceptives.
Specifically, a heterozygous p.G855R mutation in BSEP leading to highly impaired taurocholate transport was associated with non-inflammatory cholestasis and highly elevated serum bile acid levels in a young patient under the first use of an oral ethinylestradiol/gestodene combination for contraception 115 . Interestingly, the mother and the maternal grandmother of the patient, who carried the same mutation had a history of ICP. In another study, homozygosity for the alanine phenotype in position 444 of BSEP was seen in four individuals with cholestasis under oral contraceptives 104 . It is therefore tempting to think that genetically determined impairment of canalicular transporter function not only predisposes to ICP, but constitutes a risk factor to the development of bland cholestasis observed with the use of female sex hormones. It can only be speculated, whether the same genetic events are also involved in cholestasis associated with the use of anabolic steroids.
DIAGNOSTIC CRITERIA AND INCIDENCE OF DRUG INDUCED CHOLESTASIS
Drug induced liver injury including cholestasis is another form of acquired liver disease,
accounting for approximately two to five percent of hospitalizations for jaundice, ten percent of cases of hepatitis in all adults and more than 40 percent of hepatitis cases in adults older than 50 [116] [117] [118] . Drug induced liver injury causes a significant number of hospital admissions and may in severe cases necessitate liver transplantation 119 . Also, drug induced liver injury is leading to the attrition of a significant number of substances during drug development and has repeatedly been responsible for the withdrawal of drugs from the market 120, 121 . For these reasons, drug induced liver injury poses a significant burden to patient safety and the costs of modern health care systems.
The liver pathology of drug induced liver injury covers a wide spectrum of lesions from bland cholestasis to hepatitis and mixed forms 122, 123 . It occurs with many drugs through a variety of mechanisms, which might differ in their clinical presentations ranging from asymptomatic mild biochemical abnormalities to an acute illness with jaundice that resembles viral hepatitis 124 .
While good epidemiological data exist on the entire spectrum of drug-induced liver injury (for review see: 125, 126 
PATHOPHYSIOLOGY OF DRUG INDUCED CHOLESTASIS
Prior to their adverse action on hepatocytes, drugs need to be taken up into the cells. A large variety of drugs is entering hepatocytes via the OATPs expressed in the basolateral hepatocyte membrane 10, 26, 27 . Interestingly and importantly, it was recently found that the transport activity of OATPs may be directly modulated by physiologic substrates such as prostaglandins 128 or estrone-3-sulfate 129 as well as the drug clotrimazole 130 or the drug metabolite estradiol17bglucuronide 131 . Such interactions may potentially lead to different intracellular drug concentrations at comparable serum levels.
Unfortunately, the underlying pathogenetic mechanisms of drug induced liver injury often remain enigmatic. After the cloning of rat Bsep, it could be directly demonstrated that drugs known to be leading to cholestatic liver injury, such as for instance cyclosporine 132, 133 are competitive inhibitors of Bsep. Hence, this mechanism is the likely cause of cholestasis of such drugs as for example cyclosporin, rifamycin SV, rifampicin, glibenclamide 37, 44 . The Ki values of Bsep inhibition in the Sf9 cell expression system compare favorably with the Km values obtained in isolated rat liver canalicular plasma membrane vesicles 37 . Such inhibition of Bsep leads to intracellular retention of bile salts in hepatocytes, which at elevated concentrations are cytotoxic to hepatocytes 134 . Bosentan is a dual endothelin receptor antagonist, which is pharmacologically active together with one of its main metabolites. Bosentan elimination is predominantly via the biliary route. Bosentan and its metabolite enter hepatocytes by OATP1B1 and OATP1B3 mediated transport 135 . In clinical trials, it was found that bosentan caused asymptomatic, reversible transaminase elevations in some patients 136 . The incidence of bosentan induced liver injury was dose dependent and increases in plasma bile salt levels of affected individuals correlated with the aministered dose of bosentan. Furthermore, individuals, who were taking glyburide together with bosentan showed a higher incidence of liver injury than patients with a bosentan monotherapy. Experiments with rat and human BSEP expressed in Sf9 cell vesicles identified bosentan as a competitive inhibitor of BSEP 45, 136 . Rats treated with bosentan displayed an elevation of plasma bile salt levels, which further increases upon coadministration of glibenclamide 136 . Hence, as serum bile salt levels in patients positively correlated with the bosentan dose and as the serum liver parameters after stopping of bosentan spontaneous normalized, it can be concluded that bosentan acts as a competitive BSEP inhibitor. This inhibition of BSEP seems to be rather specific, as no elevation of serum bilirubin was observed 136 . Most interestingly, in a follow-up investigation of the cholestatic mechanism of bosentan in rats it was found that contrary to the expectations bosentan leads to a stimulation of bile flow Other examples include sulfinpyraznoe, penicillin G or indomethacin 139 . The consequence of drug-induced activation of MRP2 may be a lowering of the bile salt concentration in the canaliculus below a (yet unknown) threshold value followed by an alteration in canaliculaur phospholipid and cholesterol secretion 140 . Taken together, Bsep can either be inhibited directly by drug form the cytoplasm or indirectly, most probably from the canalicular side. This latter process seems to need the presence of functional Mrp2.
In addition, indirect mechanisms of BSEP inhibition requiring MRP2 have been described, such as for example for estradiol-17β-glucuronide, bosentan and for the HER1/HER2 inhibitor PKI166 37, 138, 141 . In cases, where the acquired liver disease is caused by bland cholestasis, this process is rapidly reversible upon discontinuation of the drug, as illustrated for bosentan 136 .
Taken together, many drugs as well as endogenous steroid metabolites have the potential to interfere with transport activity of Bsep. As this includes direct and indirect inhibition of BSEP as well as regulation of its carrier density in the canalicular membrane, the actual mechanism of drug induced reduction of BSEP activity may be complex for a given substance.
Troglitazone is a drug, which was withdrawn from the market due to its hepatotoxicity. The exact molecular mechanisms of its toxicity remains somewhat enigmatic, but a consensus has emerged with time that troglitazone is mainly toxic to mitochondria 142, 143 . In addition to its direct adverse action on mitochondria, troglitazone administration leads to an acute reduction to bile flow in rats. Hence troglitzone is also cholestatic drug 144 . Troglitazone is mainly metabolized into troglitazone sulfate in rats, which is subsequently excreted into bile 145 . Both, the parent compound and its sulfated metabolite are competitive inhibitors of Bsep in rat canalicular plasma membrane vesicles. Recently, troglitazone was also demonstrated to be an inhibitor of dog and human BSEP 146, 147 . Taken together, troglitazone can negatively impact mitochondria via direct toxicity as well as by inhibiting BSEP, which in turn leads to an accumulation of bile salts in 21 hepatocytes. They by themselves are at elevated intracellular concentrations toxic to mitochondria 134 . Often, drug induced liver injury results not only in cholestatic but in mixed (hepatocellular and cholestatic) liver injury 117 . A study investigating a potential class effect of thiazolidinediones on Bsep found that both rosiglitazone and ciglitazone are inhibitors of ATPdependent taurocholate transport into rat canalicular plasma membrane vesicles 147 . This is a strong indication that the toxicity of troglitazone requires multiple mechanisms for exerting its cholestatic potential.
In summary, drug induced cholestatic liver injury is a complex pathophysiologic entity including both direct and indirect effects of BSEP inhibition.
GENETICS OF DRUG INDUCED CHOLESTASIS
Investigations of the genetics of drug-induced liver injury have proved taxing, both because of their low incidence and their difficulty in replicating observed associations. Nevertheless progress has now been achieved by both candidate-gene and genome-wide association approaches. In particular, associations between antituberculosis drug-related liver injury and the "slow acetylator" genotype for N-acetyltransferase 2, amoxicillin/clavulanate-related liver injury, and the human leukocyte antigen (HLA) class II DRB1*1501 allele and flucloxacillin-related injury and the HLA class I B*5701 allele are now established 148, 149 . Although, associations are so far drug-specific, more general susceptibility genes for DILI may exist. However, elucidation of these links will requires further investigation, ideally by using large cohorts involving international collaboration. , six of which exhibited reduced in-vitro uptake of the OATP1B1 substrates estrone-3-sulfate and estradiol-17β-glucuronide. OATP1B1 genetic variants have also been associated with interindividual differences in hepatic disposition of pravastatin and irinotecan, respectively [152] [153] [154] [155] . Furthermore, the cellular uptake of the lipid-lowering drug rosuvastatin is highly dependent on NTCP and OATP function and varies upon the underlying NTCP and OATP haplotypes 156 . While the impact of these observations for the development of cholestasis remains to be studied, it could be speculated that differences in NTCP and OATP mediated basolateral drug uptake predisposes to the development of cholestasis by determining intracellular drug levels and hence, the concentration of potential competitive inhibitors of apical efflux transporters.
CONCLUSIONS
From the examples delineated in this article it is apparent that genetically determined dysfunction of hepatocellular uptake and excretion of bile salts is an important pathogenic factor for the development of cholestasis. While the genetic components of intrahepatic cholestasis of pregnancy and estrogen-induced cholestasis has clearly emerged over the last decade, the role of genetics in drug-induced cholestasis is less evident. The heterogeneous and multifactorial nature of drug-induced liver disease makes it not only challenging to clearly link liver disease to a specific drug, but so far impossible to prove the pathogenic role of a specific genetic transporter variant. Future challenges will consist in integrating different genetic determinants of drug toxicity with different environmental and comorbidity-related factors and in a comprehensive system, allowing the cautious use of problematic drugs in susceptible patients.
